These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 6364366)

  • 1. A randomized double blind crossover trial of diethylstilbestrol (DES) and estramustine phosphate (Emcyt) for stage D prostatic carcinoma.
    Benson RC; Gill GM; Cummings KB
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):43-5. PubMed ID: 6364366
    [No Abstract]   [Full Text] [Related]  

  • 2. Estramustine phosphate vs diethylstilbestrol in the treatment of stage D prostate cancer.
    Benson RC; Cummings K
    Prog Clin Biol Res; 1989; 303():177-86. PubMed ID: 2674984
    [No Abstract]   [Full Text] [Related]  

  • 3. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer.
    Murphy GP; Huben RP; Priore R
    Urology; 1986 Jul; 28(1):36-40. PubMed ID: 3523938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical relevance of plasma testosterone and prolactin changes in advanced cancer of prostate treated with diethylstilbestrol or estramustine phosphate.
    Morales A; Nickel JC
    Urology; 1985 Nov; 26(5):477-81. PubMed ID: 3904134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer.
    Benson RC; Gill GM
    Am J Clin Oncol; 1986 Aug; 9(4):341-51. PubMed ID: 3529921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. French multicenter study on the use of estramustine phosphate versus diethylstilbestrol.
    Hauchecorne J
    Prog Clin Biol Res; 1987; 243B():229-34. PubMed ID: 3309983
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer.
    Smith PH; Suciu S; Robinson MR; Richards B; Bastable JR; Glashan RW; Bouffioux C; Lardennois B; Williams RE; de Pauw M
    J Urol; 1986 Sep; 136(3):619-23. PubMed ID: 3525866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The EORTC Phase III trials in prostatic cancer.
    Robinson MR; Smith PH; Macaluso MP; Sylvester R; de Voogt H
    Prog Clin Biol Res; 1985; 185A():243-9. PubMed ID: 3898132
    [No Abstract]   [Full Text] [Related]  

  • 9. Estramustine phosphate versus stilbestrol as primary treatment for metastatic cancer of the prostate.
    Nickel CJ; Morales A
    Can J Surg; 1983 Sep; 26(5):434-8. PubMed ID: 6351988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experiences with estramustine phosphate (Estracyt, Emcyt) in prostate cancer.
    Murphy GP; Slack NH; Mittelman A
    Semin Oncol; 1983 Sep; 10(3 Suppl 3):34-42. PubMed ID: 6364365
    [No Abstract]   [Full Text] [Related]  

  • 11. Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of Protocol 30762.
    Smith PH; Robinson M; Richards B; Suciu S; De Pauw M; Sylvester R; Denis L
    Urology; 1984 Jun; 23(6 Suppl):64-8. PubMed ID: 6375083
    [No Abstract]   [Full Text] [Related]  

  • 12. Comparison of flutamide and Emcyt in hormone-refractory metastatic prostatic cancer.
    de Kernion JN; Murphy GP; Priore R
    Urology; 1988 Apr; 31(4):312-7. PubMed ID: 3281365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in white cell count during treatment of advanced cancer of the prostate with estramustine phosphate and with stilboestrol.
    Daponte D; Sylvester R; De Pauw M; Fryszman A; Smith RM; Smith PH
    Br J Urol; 1983 Aug; 55(4):408-12. PubMed ID: 6349745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estramustine phosphate as primary therapy for metastatic prostate cancer. Preliminary results of the University of Wisconsin trial.
    Benson RC
    Urology; 1984 Jun; 23(6 Suppl):69-72. PubMed ID: 6375084
    [No Abstract]   [Full Text] [Related]  

  • 15. [Plasma changes caused by estrogens in the vascular risk of prostatic carcinoma over a 3-year period].
    Daponte DP; Stevens I; Robinson MR
    Actas Urol Esp; 1986; 10(6):437-40. PubMed ID: 3825644
    [No Abstract]   [Full Text] [Related]  

  • 16. Randomised, double-blind study of estramustine phosphate and leuprolide acetate.
    De la Grange AB
    Prog Clin Biol Res; 1987; 243B():227-8. PubMed ID: 3116555
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of treatment with diethylstilbestrol-polyestradiol phosphate or estramustine phosphate (estracyt) on natural killer cell activity in patients with prostatic cancer.
    Kalland T; Haukaas S
    Invest Urol; 1981 May; 18(8):437-9. PubMed ID: 7228576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estramustine for prostate cancer.
    Med Lett Drugs Ther; 1982 Aug; 24(615):74. PubMed ID: 7099111
    [No Abstract]   [Full Text] [Related]  

  • 19. Plasma hormone levels in patients with prostatic carcinoma treated with diethylstilboestrol and estramustine.
    Bishop MC; Selby C; Taylor M
    Br J Urol; 1985 Oct; 57(5):542-7. PubMed ID: 3904908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of diethylstilbestrol and estramustine phosphate on serum sex hormone binding globulin and testosterone levels in prostate cancer patients.
    Karr JP; Wajsman Z; Kirdani RY; Murphy GP; Sandberg AA
    J Urol; 1980 Aug; 124(2):232-6. PubMed ID: 7190620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.